Specialty glass maker Schott has appointed Stefan Brandl, former chief executive of automotive supplier Dräxlmaier Group, as its new chief executive effective 1 November 2026. He succeeds Dr Torsten Derr, who steps down on 31 October 2026 for family reasons after the Supervisory Board approved early termination of his term.
Why this mattersSchott changes chief executive at four weeks' notice; the incoming CEO's long supervisory board tenure points to continuity rather than a reset for its 18,000 staff.
- Stefan Brandl becomes Schott CEO effective 1 November 2026.
- Dr Torsten Derr steps down as CEO on 31 October 2026, citing family reasons.
- Brandl was Vice Chairman and CEO of Dräxlmaier Group since 2021.
- Brandl was CEO of ebm-papst from 2017 to 2021.
- Brandl has served on Schott's Supervisory Board for many years.
- Schott employs nearly 18,000 people.
Shenzhen-listed Lynoo Pharmaceutical Packaging reported nine-month 2026 revenue up 38.78% to USD 150.5m (RMB 1.001bn). Net profit attributable to shareholders fell 19.03% to USD 6.19m (RMB 41.2m), and operating cash flow was an outflow of USD 7.8m (RMB 51.9m). Short-term borrowings rose 358.57% from end-2025. The company applied for a Hong Kong H-share listing on 28 September 2026. Proceeds are partly intended for ready-to-use packaging and pre-fillable syringes, and for a semiconductor glass substrate business that has no revenue or orders yet.
Why this mattersChina's ninth-largest pharma glass packager is raising capital abroad while profit and cash flow weaken, with proceeds partly funding a glass substrate line that has no orders yet.
- Nine-month 2026 revenue USD 150.5m (RMB 1.001bn), up 38.78% year on year
- Net profit attributable to parent USD 6.19m (RMB 41.2m), down 19.03%
- Net operating cash outflow of USD 7.8m (RMB 51.9m) for the period
- Short-term borrowings up 358.57% from end-2025
- H-share listing application submitted to HKEX on 28 September 2026
- Ranked ninth in China's pharmaceutical glass packaging market in 2025 with a 2.4% share
Shandong Linuo Pharmaceutical Packaging, listed on Shenzhen's ChiNext since November 2021, filed on 28 September 2026 for a main-board listing on the Hong Kong Stock Exchange, with China Merchants Securities International and Lego Financial Group as joint sponsors. The borosilicate glass maker ranks ninth in China's pharmaceutical glass packaging market and first in China, second globally, in daily-use heat-resistant glass. Proceeds are earmarked for industrialising semiconductor packaging glass substrates and RTU and PFS production.
Why this mattersA dual listing would give a leading Chinese borosilicate glass packaging player fresh capital to scale semiconductor glass substrates, a potential new growth line adjacent to pharma packaging.
- Filed for Hong Kong main-board listing on 28 September 2026, already listed on Shenzhen ChiNext since 11 November 2021
- Ranked 9th in China's pharmaceutical glass packaging market with 2.4% share by 2025 revenue, per Frost & Sullivan
- Ranked 1st in China and 2nd globally in daily-use heat-resistant glass, with 9.5% domestic and 5.1% global market share
- 2025 revenue was USD 146.4m (RMB 981.5m), down from USD 161.2m (RMB 1,080.8m) in 2024
- 2025 net profit was USD 5.9m (RMB 39.7m), down from USD 9.9m (RMB 66.1m) in 2024
- IPO proceeds earmarked for industrialising semiconductor packaging glass substrates and RTU and PFS production plus R&D
- Adjusted net profit for H1 2026 rose 11.9% to USD 6.8m (RMB 45.837m), even as reported net profit fell 23.9% to USD 4.7m (RMB 31.157m).
Shandong Linuo Pharmaceutical Packaging, already listed in Shenzhen as Linuo Packaging (301188.SZ), filed on 28 September 2026 for a dual Main Board listing on the Hong Kong Stock Exchange. The borosilicate glass specialist ranks second globally in heat-resistant glass for daily use with a 5.1% share and ninth in China's pharmaceutical glass packaging market. The listing filing coincides with the company's move into glass substrates for semiconductor packaging, where a pilot furnace was ignited in June 2026.
Why this mattersA dual listing would give a top-two global heat-resistant glass maker fresh capital access as it diversifies into semiconductor-grade glass substrates.
- Shandong Linuo Pharmaceutical Packaging (301188.SZ, listed in Shenzhen) filed on 28 September 2026 for a Main Board listing on the Hong Kong Stock Exchange.
- China Merchants Securities International and Lego Financial Group are joint sponsors of the HKEX listing.
- The company ranks second globally in heat-resistant glass for daily use, with a 5.1% market share, and first in China with 9.5% share, per Frost & Sullivan 2025 data.
- It ranks ninth among China pharmaceutical glass packaging suppliers, with a 2.4% market share.
- Products are sold to customers in about 60 countries across the Americas, Asia and Europe.
- A pilot furnace for glass substrates used in semiconductor packaging was ignited in June 2026, with sample provision to industry participants under way.
Schott Pharma and Nemera have launched a passive safety system pairing Schott's 5.5ml syriQ BioPure prefillable glass syringe with Nemera's Safe'n'Sound safety device, targeting subcutaneous self-injection of large-volume biologic drugs. The companies say the pre-aligned platform is already available for technical assessment and compatibility studies, and will be shown at CPHI Milan and PDA in early October 2026. They describe it as the first such combination built around a 5.5ml prefillable glass syringe.
Why this mattersA pre-validated syringe-and-safety-device combination lowers technical risk for biologics makers shifting therapies from intravenous to home subcutaneous delivery.
- The system pairs Schott Pharma's 5.5ml syriQ BioPure prefillable glass syringe with Nemera's Safe'n'Sound passive safety device.
- Launch was announced 22 September 2026.
- The companies describe it as the industry's first passive safety system built around a 5.5ml prefillable glass syringe.
- It targets subcutaneous self-injection of large-volume and biologic drugs, including homecare use.
- The product will be exhibited at CPHI Milan on 6-8 October 2026 and PDA 2026 on 6-7 October 2026.
- It is already available for technical assessment, compatibility studies and development programmes.
Schott Pharma has delivered the first full batch of vials packed in trays made with recycled polypropylene to Takeda's manufacturing site in Singen, Germany, taking a closed-loop system developed with tray maker Corplex from pilot phase into routine operation. The trays contain up to 70% recycled polypropylene drawn from a controlled loop, and a peer-reviewed independent life-cycle assessment puts their greenhouse gas emissions up to 50% below equivalent all-virgin trays. Formal change controls and trials at Takeda confirmed the trays are processable in pharmaceutical manufacturing.
Why this mattersA qualified closed-loop recycled-content system for single-use pharma intermediate packaging gives drugmakers and tray suppliers a template ahead of tighter EU rules.
- The first full batch of vials in recycled-PP trays reached Takeda's Singen site in Germany in August 2026, following a pilot phase
- The trays contain up to 70% recycled polypropylene sourced from a controlled closed loop
- A peer-reviewed independent life-cycle assessment by The LCA Centre in October 2024 found up to 50% lower greenhouse gas emissions than equivalent trays made entirely from virgin polypropylene
- Development ran over two years and included a risk assessment, a ton-scale production study and equivalency testing against virgin-material trays
- Corplex returns the closed-loop material into new tray production and Schott Pharma uses the trays as intermediate packaging for vial shipments to Takeda
- The system targets Scope 3, Category 1 emissions across the three companies' value chain
